Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21944929 | 0.88 | IDO1 (0.42) | MRGPRX4L3MBTL1IDO1MAOBMAPT | |
| SCHEMBL21945065 | 0.85 | CYP4F2 (0.41) | MRGPRX4IDO1MAOB | |
| SCHEMBL21944794 | 0.82 | IDO1 (0.42) | MRGPRX4L3MBTL1IDO1MAOBMAPT | |
| SCHEMBL21944924 | 0.82 | MRGPRX4 (0.42) | MRGPRX4L3MBTL1TDP1EPAS1 | |
| SCHEMBL18002794 | 0.82 | MAOA (0.41) | MRGPRX4L3MBTL1TDP1IDO1MAOB | |
| SCHEMBL21945062 | 0.81 | NR4A2 (0.49) | MRGPRX4L3MBTL1MAOBMAPTPOLB | |
| SCHEMBL21944825 | 0.80 | IDO1 (0.53) | MRGPRX4L3MBTL1IDO1MAOBTACR1 | |
| SCHEMBL21945045 | 0.80 | MAOB (0.54) | MRGPRX4IDO1MAOB | |
| SCHEMBL21945509 | 0.79 | MAOB (0.59) | MRGPRX4L3MBTL1IDO1MAOBMAPT | |
| SCHEMBL26604865 | 0.75 | MRGPRX4 (0.46) | MRGPRX4MAOBMAPTPOLBHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | MRGPRX4 4062/4885L3MBTL1 1503/4885TDP1 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.